Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Novartis Wins First U.S. Review Voucher
by Lisa M. Jarvis
April 20, 2009
| A version of this story appeared in
Volume 87, Issue 16
Novartis has received FDA approval for Coartem, the first artemisinin-based combination treatment for malaria to be approved in the U.S. In conjunction with the approval, Novartis also wins the first priority review voucher (PRV), a coupon good for expediting the review of any other New Drug Application. PRVs are only awarded with the approval of novel drugs for neglected diseases and can be sold to another firm. FDA introduced the vouchers in 2007 to entice companies to devote research dollars to diseases that primarily affect developing countries (C&EN, Jan. 19, page 38).
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter